Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications

被引:677
作者
Harirforoosh, Sam [1 ]
Asghar, Waheed [2 ]
Jamali, Fakhreddin [2 ]
机构
[1] E Tennessee State Univ, Gatton Coll Pharm, Dept Pharmaceut Sci, Johnson City, TN 37614 USA
[2] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2E1, Canada
关键词
ACUTE MYOCARDIAL-INFARCTION; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; CONTROLLED CLINICAL-TRIAL; ALL-CAUSE MORTALITY; BLOOD-PRESSURE; RHEUMATOID-ARTHRITIS; NONSELECTIVE NSAIDS; COX-2; INHIBITORS; POOLED ANALYSIS; DOUBLE-BLIND;
D O I
10.18433/J3VW2F
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Non-steroidal anti-inflammatory drugs (NSAIDs) are used chronically to reduce pain and inflammation in patients with arthritic conditions, and also acutely as analgesics by many patients. Both therapeutic and adverse effects of NSAIDs are due to inhibition of cyclooxygenase (COX) enzyme. NSAIDs are classified as non-selective and COX-2-selective inhibitors (COXIBS) based on their extent of selectivity for COX inhibition. However, regardless of their COX selectivity, reports are still appearing on the GI side effect of NSAIDs particularly on the lower gastrointestinal (GI) tract and the harmful role of their controlled release formulations. In addition, previously unpublished data stored in the sponsor's files, question the GI sparing properties of rofecoxib, a COXIB that has been withdrawn due to cardiovascular (CV) side effects. Presently, the major side effects of NSAIDs are the GI complications, renal disturbances and CV events. There is a tendency to believe that all NSAIDs are associated with renal and CV side effects, a belief that is not supported by solid evidence. Indeed, lower but still therapeutics doses of some NSAIDs may be cardioprotective. In this review, we briefly discuss the GI toxicity of the NSAIDs and assess their renal and CV adverse effects in more detail.
引用
收藏
页码:821 / 847
页数:27
相关论文
共 203 条
[41]
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease [J].
Cote, Sharlene ;
Carmichael, Pierre-Hugues ;
Verreault, Rene ;
Lindsay, Joan ;
Lefebvre, Jean ;
Laurin, Danielle .
ALZHEIMERS & DEMENTIA, 2012, 8 (03) :219-226
[42]
Prevalence of gastroprotective agent (GPA) use in adults with arthritis in the United States [J].
Coyne, Karin S. ;
Margolis, Mary Kay ;
Cappelleri, Joseph C. ;
Hsieh, Ray ;
Essex, Margaret Noyes ;
Park, Peter W. ;
Joshi, Ashish V. .
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (05) :421-433
[43]
Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8 [J].
Curfman, GD ;
Morrissey, S ;
Drazen, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (26) :2813-2814
[44]
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis [J].
Curtis, Jeffrey R. ;
Lanas, Angel ;
John, Ani ;
Johnson, David A. ;
Schulman, Kathy L. .
ARTHRITIS CARE & RESEARCH, 2012, 64 (12) :1819-1828
[45]
Protective effects of angiotensin II interruption: Evidence for antiinflammatory actions [J].
Dagenais, NJ ;
Jamali, F .
PHARMACOTHERAPY, 2005, 25 (09) :1213-1229
[46]
Davies NM, 1999, J PHARM PHARM SCI, V2, P5
[47]
Davies NM, 2004, J PHARM PHARM SCI, V7, P217
[48]
Influence of dosage form on the gastroenteropathy of flurbiprofen in the rat: Evidence of shift in the toxicity site [J].
Davies, NM ;
Jamali, F .
PHARMACEUTICAL RESEARCH, 1997, 14 (11) :1597-1600
[49]
Misoprostol therapeutics revisited [J].
Davies, NM ;
Longstreth, J ;
Jamali, F .
PHARMACOTHERAPY, 2001, 21 (01) :60-73
[50]
Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers [J].
Davies, NM ;
Jamali, F .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1997, 16 (07) :345-349